A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Iron sucrose (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions
- Sponsors Luitpold Pharmaceuticals
- 06 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.
- 06 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.